Weina Ma, Man Zhu, Bo Wang, Zhengyan Gong, Xia Du, Tianfeng Yang, Xianpeng Shi, B. Dai, Y. Zhan, Dongdong Zhang, Yanhong Ji, Yang Wang, Song Li, Yanmin Zhang
{"title":"Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type‐B receptor 4","authors":"Weina Ma, Man Zhu, Bo Wang, Zhengyan Gong, Xia Du, Tianfeng Yang, Xianpeng Shi, B. Dai, Y. Zhan, Dongdong Zhang, Yanhong Ji, Yang Wang, Song Li, Yanmin Zhang","doi":"10.1002/1878-0261.13270","DOIUrl":"https://doi.org/10.1002/1878-0261.13270","url":null,"abstract":"The oncogenic role of ephrin type‐B receptor 4 (EPHB4) has been reported in many types of tumors, including chronic myeloid leukemia (CML). Here, we found that CML patients have a higher EPHB4 expression level than healthy subjects. EPHB4 knockdown inhibited growth of K562 cells (a human immortalized myelogenous leukemia cell line). In addition, transient transfection of EPHB4 siRNA led to sensitization to imatinib. These growth defects could be fully rescued by EPHB4 transfection. To identify an EPHB4‐specific inhibitor with the potential of rapid translation into the clinic, a pool of clinical compounds was screened and vandetanib was found to be most sensitive to K562 cells, which express a high level of EPHB4. Vandetanib mainly acts on the intracellular tyrosine kinase domain and interacts stably with a hydrophobic pocket. Furthermore, vandetanib downregulated EPHB4 protein via the ubiquitin‐proteasome pathway and inhibited PI3K/AKT and MAPK/ERK signaling pathways in K562 cells. Vandetanib alone significantly inhibited tumor growth in a K562 xenograft model. Furthermore, the combination of vandetanib and imatinib exhibited enhanced and synergistic growth inhibition against imatinib‐resistant K562 cells in vitro and in vivo. These findings suggest that vandetanib drives growth arrest and overcomes the resistance to imatinib in CML via targeting EPHB4.","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2747 - 2765"},"PeriodicalIF":6.6,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44369767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Corrigendum to: iRGD‐modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation","authors":"","doi":"10.1002/1878-0261.13258","DOIUrl":"https://doi.org/10.1002/1878-0261.13258","url":null,"abstract":"Lin et al. [1] would like to correct Fig. 4B as errors were introduced in the preparation of these figures for publication. The authors were able to provide to the journal the raw data underlying all experimental replicates. The journal has reviewed replicate raw data and the Editors and Authors confirm that correction of this error has not altered the interpretation of data and did not affect the conclusions presented in the article. The authors sincerely apologise for their mistake and for any inconvenience caused.","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2607 - 2608"},"PeriodicalIF":6.6,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47750752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Otto, C. Kastner, S. Schmidt, Konstantin L. Uttinger, Apoorva Baluapuri, S. Denk, M. Rosenfeldt, A. Rosenwald, F. Roehrig, C. Ade, Christina Schuelein-Voelk, M. Diefenbacher, Christoph‐Thomas Germer, E. Wolf, M. Eilers, A. Wiegering
{"title":"RNA polymerase I inhibition induces terminal differentiation, growth arrest, and vulnerability to senolytics in colorectal cancer cells","authors":"C. Otto, C. Kastner, S. Schmidt, Konstantin L. Uttinger, Apoorva Baluapuri, S. Denk, M. Rosenfeldt, A. Rosenwald, F. Roehrig, C. Ade, Christina Schuelein-Voelk, M. Diefenbacher, Christoph‐Thomas Germer, E. Wolf, M. Eilers, A. Wiegering","doi":"10.1002/1878-0261.13265","DOIUrl":"https://doi.org/10.1002/1878-0261.13265","url":null,"abstract":"Ribosomal biogenesis and protein synthesis are deregulated in most cancers, suggesting that interfering with translation machinery may hold significant therapeutic potential. Here, we show that loss of the tumor suppressor adenomatous polyposis coli (APC), which constitutes the initiating event in the adenoma carcinoma sequence for colorectal cancer (CRC), induces the expression of RNA polymerase I (RNAPOL1) transcription machinery, and subsequently upregulates ribosomal DNA (rDNA) transcription. Targeting RNAPOL1 with a specific inhibitor, CX5461, disrupts nucleolar integrity, and induces a disbalance of ribosomal proteins. Surprisingly, CX5461‐induced growth arrest is irreversible and exhibits features of senescence and terminal differentiation. Mechanistically, CX5461 promotes differentiation in an MYC‐interacting zinc‐finger protein 1 (MIZ1)‐ and retinoblastoma protein (Rb)‐dependent manner. In addition, the inhibition of RNAPOL1 renders CRC cells vulnerable towards senolytic agents. We validated this therapeutic effect of CX5461 in murine‐ and patient‐derived organoids, and in a xenograft mouse model. These results show that targeting ribosomal biogenesis together with targeting the consecutive, senescent phenotype using approved drugs is a new therapeutic approach, which can rapidly be transferred from bench to bedside.","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2788 - 2809"},"PeriodicalIF":6.6,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45440442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Targeting cellular senescence to combat cancer and ageing","authors":"Chen Wang, Xue Hao, Rugang Zhang","doi":"10.1002/1878-0261.13266","DOIUrl":"https://doi.org/10.1002/1878-0261.13266","url":null,"abstract":"Senescence is a complex cellular process that is implicated in various physiological and pathological processes. It is characterized by a stable state of cell growth arrest and by a secretome of diverse pro‐inflammatory factors, chemokines and growth factors. In this review, we summarize the context‐dependent role of cellular senescence in ageing and in age‐related diseases, such as cancer. We discuss current approaches to targeting senescence to develop therapeutic strategies to combat cancer and to promote healthy ageing, and we outline our vision for future research directions for senescence‐based interventions in these fields.","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"3319 - 3332"},"PeriodicalIF":6.6,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46299259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ya Li, Zhenwei Song, Qiuju Han, Huajun Zhao, Zhaoyi Pan, Z. Lei, Jian Zhang
{"title":"Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis","authors":"Ya Li, Zhenwei Song, Qiuju Han, Huajun Zhao, Zhaoyi Pan, Z. Lei, Jian Zhang","doi":"10.1002/1878-0261.13263","DOIUrl":"https://doi.org/10.1002/1878-0261.13263","url":null,"abstract":"In hepatocellular carcinoma (HCC), the signal transducer and activator of transcription 3 (STAT3) is present in an overactive state that is closely related to tumour development and immune escape. STAT3 inhibition reshapes the tumour immune microenvironment, but the underlying mechanisms have not been fully clarified. We found that STAT3 inhibition could induce immunogenic cell death (ICD) of HCC cells via translocation of the “eat me” molecule calreticulin to the cell surface and a significant reduction in the expression of the “don’t eat me” molecule leucocyte surface antigen CD47. STAT3 inhibition promoted dendritic cell (DC) activation and enhanced the recognition and phagocytosis of HCC cells by macrophages. Furthermore, STAT3 inhibition prevented the expression of key glycolytic enzymes, facilitating the induction of ICD in HCC. Interestingly, STAT3 directly regulated the transcription of CD47 and solute carrier family 2 member 1 (SLC2A1; also known as GLUT1). In subcutaneous and orthotopic transplantation mouse tumour models, the STAT3 inhibitor napabucasin prevented tumour growth and induced the expression of calreticulin and the protein disulfide isomerase family A member 3 (PDIA3; also known as ERp57) but suppressed that of CD47 and GLUT1. Meanwhile, the amount of tumour‐infiltrated DCs and macrophages increased, along with the expression of costimulatory molecules. More CD4+ and CD8+ T cells accumulated in tumour tissues, and CD8+ T cells had lower expression of checkpoint molecules such as lymphocyte activation gene 3 protein (LAG‐3) and programmed cell death protein 1 (PD‐1). Significantly, the antitumour immune memory response was induced by treatment targeting STAT3. These findings provide a new mechanism for targeting STAT3‐induced ICD in HCC, and confirms STAT3 as a potential target for the treatment of HCC via reshaping the tumour immune microenvironment.","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2861 - 2880"},"PeriodicalIF":6.6,"publicationDate":"2022-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43065349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Łysiak, Małgorzata Trybuła, M. Mudaisi, C. Bratthäll, M. Strandeus, P. Milos, M. Hallbeck, A. Malmström
{"title":"The sex‐dependent role of the androgen receptor in glioblastoma: results of molecular analyses","authors":"M. Łysiak, Małgorzata Trybuła, M. Mudaisi, C. Bratthäll, M. Strandeus, P. Milos, M. Hallbeck, A. Malmström","doi":"10.1002/1878-0261.13262","DOIUrl":"https://doi.org/10.1002/1878-0261.13262","url":null,"abstract":"We sought to analyse the androgen receptor (AR) in glioblastoma (GBM) due to the location of the AR gene on chromosome X, often reported with shorter survival and higher prevalence of GBM among males. Copy number (CN) and mRNA expression of AR were tested with droplet digital PCR in 91 fresh‐frozen GBM samples and 170 formalin‐fixed, paraffin‐embedded samples collected at Linköping University Hospital. The fresh‐frozen cohort was also subjected to pyrosequencing methylation analysis of 17 CpG sites in the AR promoter. Additionally, the gene expression of AR was analysed in the fresh‐frozen cohort and The Cancer Genome Atlas (TCGA) cohort of isocitrate dehydrogenase wild‐type primary GBM (135 females and 219 males). The association of AR expression and overall survival (OS) was tested with Kaplan–Meier log rank analysis after dichotomisation by maximally selected rank statistics. We found that AR CN alterations were more common in female GBM. AR gene expression correlated with methylation levels of different CpG sites in males and females but there was no difference in expression between sexes. Survival analysis of TCGA cohort revealed the opposite effect of AR overexpression on OS of males and females, with high AR expression correlating with shorter OS in females and longer OS in males. Additional gene set enrichment analysis showed that AR expression correlated with DNA repair response, especially in the male group. In summary, we found that high AR gene expression in GBM exhibits sex‐dependent effects on patient survival, which, for males, is linked to DNA repair response.","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"3436 - 3451"},"PeriodicalIF":6.6,"publicationDate":"2022-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46398931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Niger, F. Nichetti, A. Casadei‐Gardini, F. Morano, C. Pircher, E. Tamborini, F. Perrone, M. Canale, D. Lipka, A. Vingiani, L. Agnelli, A. Dobberkau, J. Hüllein, Felix Korell, C. Heilig, S. Pusceddu, F. Corti, M. Droz, P. Ulivi, M. Prisciandaro, M. Antista, M. Bini, L. Cattaneo, M. Milione, H. Glimm, B. Köhler, G. Pruneri, D. Hübschmann, S. Fröhling, V. Mazzaferro, F. Pietrantonio, M. Di Bartolomeo, F. de Braud
{"title":"MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers","authors":"M. Niger, F. Nichetti, A. Casadei‐Gardini, F. Morano, C. Pircher, E. Tamborini, F. Perrone, M. Canale, D. Lipka, A. Vingiani, L. Agnelli, A. Dobberkau, J. Hüllein, Felix Korell, C. Heilig, S. Pusceddu, F. Corti, M. Droz, P. Ulivi, M. Prisciandaro, M. Antista, M. Bini, L. Cattaneo, M. Milione, H. Glimm, B. Köhler, G. Pruneri, D. Hübschmann, S. Fröhling, V. Mazzaferro, F. Pietrantonio, M. Di Bartolomeo, F. de Braud","doi":"10.1002/1878-0261.13256","DOIUrl":"https://doi.org/10.1002/1878-0261.13256","url":null,"abstract":"Biliary tract cancers (BTCs) have poor prognosis and limited therapeutic options. The impact of O6‐methylguanine‐DNA methyltransferase (MGMT) inactivation in advanced BTC patients is not established. We investigated the prevalence, prognostic, and predictive impact of MGMT inactivation in two multicenter cohorts. MGMT inactivation was assessed through PCR and immunohistochemistry (IHC) in an Italian cohort; the results were then externally validated using RNA sequencing (RNA‐seq) data from the BTC subcohort of the Molecularly Aided Stratification for Tumor Eradication Research (MASTER) precision oncology program of the National Center for Tumor Diseases Heidelberg and the German Cancer Consortium. Among 164 Italian cases, 18% presented MGMT promoter hypermethylation (> 14%) and 73% had negative MGMT protein expression. Both were associated with worse overall survival (OS; HR 2.31; P < 0.001 and HR 1.99, P = 0.012, respectively). In the MASTER cohort, patients with lower MGMT mRNA expression showed significantly poorer OS (median OS [mOS] 20.4 vs 31.7 months, unadjusted HR 1.89; P = 0.043). Our results suggest that MGMT inactivation is a frequent epigenetic alteration in BTC, with a significant prognostic impact, and provide the rationale to explore DNA‐damaging agents in MGMT‐inactivated BTCs.","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2733 - 2746"},"PeriodicalIF":6.6,"publicationDate":"2022-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44275522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
María Garranzo-Asensio, J. Rodriguez-Cobos, C. S. Millán, C. Poves, M. Fernández-Aceñero, Daniel Pastor-Morate, D. Viñal, A. Montero‐Calle, G. Solís‐Fernández, M. Cerón, Manuel Gámez-Chiachio, N. Rodríguez, A. Guzman-Aranguez, R. Barderas, Gemma Domínguez
{"title":"In‐depth proteomics characterization of ∆Np73 effectors identifies key proteins with diagnostic potential implicated in lymphangiogenesis, vasculogenesis and metastasis in colorectal cancer","authors":"María Garranzo-Asensio, J. Rodriguez-Cobos, C. S. Millán, C. Poves, M. Fernández-Aceñero, Daniel Pastor-Morate, D. Viñal, A. Montero‐Calle, G. Solís‐Fernández, M. Cerón, Manuel Gámez-Chiachio, N. Rodríguez, A. Guzman-Aranguez, R. Barderas, Gemma Domínguez","doi":"10.1002/1878-0261.13228","DOIUrl":"https://doi.org/10.1002/1878-0261.13228","url":null,"abstract":"Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer‐related death worldwide. Alterations in proteins of the p53‐family are a common event in CRC. ΔNp73, a p53‐family member, shows oncogenic properties and its effectors are largely unknown. We performed an in‐depth proteomics characterization of transcriptional control by ∆Np73 of the secretome of human colon cancer cells and validated its clinical potential. The secretome was analyzed using high‐density antibody microarrays and stable isotopic metabolic labeling. Validation was performed by semiquantitative PCR, ELISA, dot‐blot and western blot analysis. Evaluation of selected effectors was carried out using 60 plasma samples from CRC patients, individuals carrying premalignant colorectal lesions and colonoscopy‐negative controls. In total, 51 dysregulated proteins were observed showing at least 1.5‐foldchange in expression. We found an important association between the overexpression of ∆Np73 and effectors related to lymphangiogenesis, vasculogenesis and metastasis, such as brain‐derived neurotrophic factor (BDNF) and the putative aminoacyl tRNA synthase complex‐interacting multifunctional protein 1 (EMAP‐II)–vascular endothelial growth factor C–vascular endothelial growth factor receptor 3 axis. We further demonstrated the usefulness of BDNF as a potential CRC biomarker able to discriminate between CRC patients and premalignant individuals from controls with high sensitivity and specificity.","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2672 - 2692"},"PeriodicalIF":6.6,"publicationDate":"2022-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43942494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Auchi Inalegwu, Bart Cuypers, J. Claesen, A. Janssen, Amelie Coolkens, S. Baatout, K. Laukens, W. D. De Vos, R. Quintens
{"title":"Fractionated irradiation of MCF7 breast cancer cells rewires a gene regulatory circuit towards a treatment‐resistant stemness phenotype","authors":"Auchi Inalegwu, Bart Cuypers, J. Claesen, A. Janssen, Amelie Coolkens, S. Baatout, K. Laukens, W. D. De Vos, R. Quintens","doi":"10.1002/1878-0261.13226","DOIUrl":"https://doi.org/10.1002/1878-0261.13226","url":null,"abstract":"Radiotherapy is the standard of care for breast cancer. However, surviving radioresistant cells can repopulate following treatment and provoke relapse. Better understanding of the molecular mechanisms of radiation resistance may help to improve treatment of radioresistant tumours. To emulate radiation therapy at the cellular level, we exposed MCF7 breast cancer cells to daily radiation doses of 2 Gy up to an accumulated dose of 20 Gy. Fractionally irradiated cells (FIR20) displayed increased clonogenic survival and population doubling time as compared with age‐matched sham‐irradiated cells and untreated parental MCF7 cells. RNA‐sequencing revealed a core signature of 229 mRNAs and 7 circular RNAs of which the expression was significantly altered in FIR20 cells. Dysregulation of several top genes was mirrored at the protein level. The FIR20 cell transcriptome overlapped significantly with canonical radiation response signatures and demonstrated a remarkable commonality with radiation and endocrine therapy resistance expression profiles, suggesting crosstalk between both acquired resistance pathways, as indicated by reduced sensitivity to tamoxifen cytotoxicity of FIR20 cells. Using predictive analyses and functional enrichment, we identified a gene‐regulatory network that promotes stemness and inflammatory signalling in FIR20 cells. We propose that these phenotypic traits render breast cancer cells more radioresistant but may at the same time serve as potential targets for combination therapies.","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"3410 - 3435"},"PeriodicalIF":6.6,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42697242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}